Mativ (NYSE:MATV – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.22 by ($0.17), Zacks reports. Mativ had a net margin of 5.44% and a return on equity of 4.88%. The firm had revenue of $458.60 million for the quarter, compared to analysts’ expectations of $472.70 million.
Mativ Stock Down 10.4 %
MATV stock traded down $0.95 during trading on Thursday, hitting $8.14. 91,455 shares of the stock traded hands, compared to its average volume of 424,137. Mativ has a 1 year low of $8.27 and a 1 year high of $19.96. The firm’s 50 day moving average is $10.12 and its two-hundred day moving average is $13.96. The stock has a market cap of $442.38 million, a price-to-earnings ratio of 4.19, a price-to-earnings-growth ratio of 1.31 and a beta of 0.66. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.37 and a quick ratio of 1.29.
Analyst Ratings Changes
Separately, Stifel Nicolaus assumed coverage on shares of Mativ in a research report on Thursday, November 21st. They set a “hold” rating and a $15.50 price objective on the stock.
Mativ Company Profile
Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.
See Also
- Five stocks we like better than Mativ
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- 5 discounted opportunities for dividend growth investors
- Should You Hold Nvidia Stock for the Long Haul or Trade It?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for Mativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mativ and related companies with MarketBeat.com's FREE daily email newsletter.